The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial.
 
Charles B. Nguyen
No Relationships to Disclose
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Aveo; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Merck Serono; Pfizer; Pfizer/Astellas; Sanofi/Aventis
Speakers' Bureau - Astellas Pharma; Bayer; Exelixis
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Matthew T Campbell
Honoraria - Axdev; Curio Science; Eisai; Exelixis; MJH Life Sciences; Seagen; Targeted Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; Exelixis; SeaGen
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Roserika Brooks
No Relationships to Disclose
 
Travis Solley
No Relationships to Disclose
 
Lauren Michelle Wood
No Relationships to Disclose
 
Eric Jonasch
Consulting or Advisory Role - Aveo; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Merck; NiKang Therapeutics; Novartis; Takeda; Telix Pharmaceuticals
Research Funding - Abbvie (Inst); Arrowhead Pharmaceuticals (Inst); Aveo (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst); ProfoundBio (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck